Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | VNN1 | O95497 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25668252 | 0.83 | CYP1A2 (0.43) | POLBTSHRCYP2D6CYP2C9CYP1A2 | |
| SCHEMBL10101641 | 0.81 | POLB (0.45) | POLBVNN1 | |
| SCHEMBL17035437 | 0.81 | POLB (0.54) | POLBTSHRCYP2D6CYP2C9CYP1A2 | |
| SCHEMBL22028181 | 0.77 | POLB (0.42) | POLBTSHRCYP2D6CYP2C9CYP1A2 | |
| SCHEMBL15221484 | 0.76 | TSHR (0.61) | VNN1TSHRCYP2D6CYP3A4 | |
| SCHEMBL26885369 | 0.76 | CYP2D6 (0.47) | VNN1TSHRCYP2D6CYP2C9CYP1A2 | |
| SCHEMBL22359044 | 0.76 | CYP2D6 (0.51) | TSHRCYP2D6CYP2C9CYP1A2ALDH1A1 | |
| SCHEMBL22358967 | 0.75 | TSHR (0.45) | VNN1TSHRCYP2D6CYP2C9CYP1A2 | |
| SCHEMBL26868402 | 0.75 | ALDH1A1 (0.47) | VNN1TSHRCYP2D6ALDH1A1CYP3A4 | |
| SCHEMBL22028187 | 0.74 | POLB (0.47) | POLBTSHRCYP2D6CYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354418-B2 | Thiazolyl-dihydro-quinazolines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-15 | — | — | US | disclosed |
| US-20090131424-A1 | THIAZOLYL-DIHYDRO-CHINAZOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-21 | — | — | US | disclosed |
| US-7517995-B2 | Thiazolyl-dihydro-cyclopentapyrazole | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-14 | — | — | US | disclosed |
| US-20070259855-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
| US-20070238746-A1 | THIAZOLYL-DIHYDRO-CHINAZOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
| US-20070238730-A1 | THIAZOLYL-DIHYDRO-CYCLOPENTAPYRAZOLE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259855-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | ROR1, RORB, RORA | POLB 3740/4885VNN1 4874/4885TSHR 249/4885 |
| US-20070238746-A1 | THIAZOLYL-DIHYDRO-CHINAZOLINE | CYP3A7, UGT2B7, UGT1A7 | POLB 3678/4885VNN1 4814/4885TSHR 210/4885 |
| US-20090131424-A1 | THIAZOLYL-DIHYDRO-CHINAZOLINE | CYP3A7, UGT2B7, UGT1A7 | POLB 3678/4885VNN1 4814/4885TSHR 210/4885 |
| US-20070238730-A1 | THIAZOLYL-DIHYDRO-CYCLOPENTAPYRAZOLE | REN, ROR1, RORB | POLB 3665/4885VNN1 4874/4885TSHR 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.